<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741464</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0142</org_study_id>
    <nct_id>NCT04741464</nct_id>
  </id_info>
  <brief_title>Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis</brief_title>
  <acronym>Aticks Live</acronym>
  <official_title>Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anticoagulants influence either coagulation, inflammation and inflammatory processes in deep&#xD;
      vein thrombosis (DVT). Acute DVT cause an inflammatory response that may persist for a long&#xD;
      period of time. There is a need to describe patterns of change in serum biomarker levels&#xD;
      after acute DVT, and explore the association between trajectory biological patterns and&#xD;
      clinical evolution in the era of various anticoagulants in the acute phase of treatment in&#xD;
      order to be able to further avoid recurrence and late sequelae. It appears that direct oral&#xD;
      anticoagulants and heparin alter inflammatory markers in different ways. It is therefore&#xD;
      important to study the evolution of markers according to the different treatments used and&#xD;
      secondarily to compare them with each other. Tinzaparin is used in the long term in patients&#xD;
      with DVT, it is necessary to measure the evolution of inflammatory markers and then in&#xD;
      another study to compare with the other molecules.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>I-CAM levels variation in acute DVT patient</measure>
    <time_frame>one year</time_frame>
    <description>The main objective of the present study is to illustrate the I-CAM serum levels decrease after an acute DVT.</description>
  </primary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Inflammatory Response</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin</intervention_name>
    <description>Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.&#xD;
Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with a first episode of symptomatic, proximal DVT of the lower limbs,&#xD;
             confirmed by Duplex Ultrasound (DUS)&#xD;
&#xD;
          -  Indication for treatment with Tinzaparin&#xD;
&#xD;
          -  Patient covered by French national health insurance,&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent DVT (less than 2 months) objectively proven by venous ultrasound - Severe&#xD;
             ilio-femoral DVT requiring recanalization&#xD;
&#xD;
          -  Duration of treatment of more than 24 h since diagnosis&#xD;
&#xD;
          -  Patients with acute symptoms (leg pain and swelling) for more than 5 days&#xD;
&#xD;
          -  Planned surgery in the following 3 weeks, impossible to postpone&#xD;
&#xD;
          -  Active haemorrhage or high risk of haemorrhage&#xD;
&#xD;
          -  Symptoms of Post Thrombotic Syndrome&#xD;
&#xD;
          -  Active neoplasm&#xD;
&#xD;
          -  APL syndrome&#xD;
&#xD;
          -  Renal insufficiency (Creatinine clearance (Cockcroft-Gault) &lt;20 mL/min)&#xD;
&#xD;
          -  Hepatic disease / or Hepatic Insufficiency / or serious liver disease&#xD;
&#xD;
          -  Hyperkaliemia more than 5 mmol/L&#xD;
&#xD;
          -  Patients with mechanical prosthetic heart valve&#xD;
&#xD;
          -  weight more than 105 kgs in order to avoid difficulties with a dosage of 20000UI OF&#xD;
             TINZAPARIN Any anti-inflammatory drugs or anti-platelet therapy&#xD;
&#xD;
          -  Any other concomitant anticoagulant treatment such as VKA, heparin, fondaparinux and&#xD;
             direct oral anticoagulants&#xD;
&#xD;
          -  Contraindications to tinzaparin according to their SmPC&#xD;
&#xD;
          -  Patient with asthma, If patients need to receive tinzaparin 10000UI antiX-a/0.5ml for&#xD;
             the study,(due to sodium metabisulfite in the solution)&#xD;
&#xD;
          -  Pregnant women or breastfeeding&#xD;
&#xD;
          -  patient with age under 18&#xD;
&#xD;
          -  Patient deprived of liberty by administrative or judicial decision or placed under&#xD;
             judicial protection (guardianship or supervision)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie-Antoinette Sevestre, Pr</last_name>
    <phone>0322087290</phone>
    <email>sevestre.marie-antoinette@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sevestre Marie-Antoinette, Pr</last_name>
      <phone>0322087290</phone>
      <email>sevestre.marie-antoinette@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Inflammatory Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

